Tao Lin, Wessam Ibrahim, Cheng‐Yuan Peng, Milton J. Finegold, Robert Y.L. Tsai – 28 June 2013 – During liver development and regeneration, hepatocytes undergo rapid cell division and face an increased risk of DNA damage associated with active DNA replication. The mechanism that protects proliferating hepatocytes from replication‐induced DNA damage remains unclear. Nucleostemin (NS) is known to be up‐regulated during liver regeneration, and loss of NS is associated with increased DNA damage in cancer cells.

Alexander Wree, Akiko Eguchi, Matthew D. McGeough, Carla A. Pena, Casey D. Johnson, Ali Canbay, Hal M. Hoffman, Ariel E. Feldstein – 28 June 2013 – Inflammasome activation plays a central role in the development of drug‐induced and obesity‐associated liver disease. However, the sources and mechanisms of inflammasome‐mediated liver damage remain poorly understood. Our aim was to investigate the effect of NLRP3 inflammasome activation on the liver using novel mouse models.

Shiv Kumar Sarin, Chandan Kumar – 28 June 2013

Helen S. Te – 28 June 2013

Peter Fickert, Elisabeth Krones, Marion J. Pollheimer, Andrea Thueringer, Tarek Moustafa, Dagmar Silbert, Emina Halilbasic, Min Yang, Hartmut Jaeschke, Geurt Stokman, Rebecca G. Wells, Kathrin Eller, Alexander R. Rosenkranz, Gosta Eggertsen, Carsten A. Wagner, Cord Langner, Helmut Denk, Michael Trauner – 28 June 2013 – Tubular epithelial injury represents an underestimated but important cause of renal dysfunction in patients with cholestasis and advanced liver disease, but the underlying mechanisms are unclear.

Stefan Mauss, Dietrich Hueppe, Ulrich Alshuth – 28 June 2013 – In clinical trials with telaprevir (TLV) and boceprevir (BOC) renal impairment was not reported as a relevant adverse event. The PAN study is a noninterventional study enrolling patients treated with peginterferon alfa‐2a/ribavirin (PEG/RBV) with or without TVL or BOC. Here we restrict the analysis to hepatitis C virus genotype 1 patients having completed 12 (n = 895) or 24 weeks (n = 591) of treatment.

Michael R. Charlton – 27 June 2013

Jacek B. Cywinski, Jing You, Maged Argalious, Samuel Irefin, Brian M. Parker, John J. Fung, Colleen G. Koch – 27 June 2013 – Investigations have demonstrated conflicting results regarding the influence of the red blood cell (RBC) storage duration on outcomes. We evaluated whether graft failure or mortality after orthotopic liver transplantation (OLT) increased when recipients were transfused with older RBCs. This study included 637 patients who underwent OLT between January 2001 and June 2011.

Garrett R. Leonard, Hiroko Shike, Tadahiro Uemura, Justine L. Gaspari, Francesca M. Ruggiero, Riaz A. Shah, Thomas R. Riley, Zakiyah Kadry – 24 June 2013 – A positive crossmatch has been associated with increased risk in liver transplantation. To study the clinical significance of preformed donor‐specific human leukocyte antigen antibodies (DSAs) in liver transplantation, we reviewed patients who underwent liver transplantation with a strongly positive flow cytometry crossmatch. DSAs were evaluated with a Luminex solid phase assay.

Vicente Arroyo, Javier Fernández – 21 June 2013 – Watch a video presentation of this article